Can You Switch from Apixaban to Enoxaparin?
Yes, you can switch from apixaban to enoxaparin—simply discontinue apixaban and begin enoxaparin at the usual time of the next scheduled apixaban dose. This transition is straightforward and does not require bridging or overlap.
How to Make the Switch
The FDA-approved prescribing information for apixaban (Eliquis) provides clear guidance 1:
- Stop apixaban completely
- Start enoxaparin at the time the next dose of apixaban would have been due
- No bridging or overlap period is needed
This approach applies whether you're switching for logistical reasons (e.g., hospitalization, inability to take oral medications), cost considerations, or clinical circumstances requiring parenteral anticoagulation.
Clinical Context Matters
When This Switch Makes Sense:
- Perioperative management: When a patient needs surgery and you want more precise control over anticoagulation timing
- NPO status: Patients who cannot take oral medications (ICU admission, GI issues, pre-procedure)
- Renal dysfunction: Severe renal impairment (CrCl <15-25 mL/min) where apixaban dosing becomes problematic 1
- Cancer-associated VTE: While apixaban is now preferred for cancer-associated thrombosis 2, enoxaparin remains an acceptable alternative, particularly for patients with GI malignancies at high bleeding risk 3
Important Caveats:
Do NOT switch back and forth repeatedly. While the evidence specifically addresses enoxaparin-to-UFH switches (which increase bleeding risk 4, 5), the principle of avoiding unnecessary anticoagulant transitions applies broadly. Each switch introduces potential for dosing errors and gaps in coverage.
Pharmacokinetic Considerations
Research demonstrates that enoxaparin does not affect apixaban pharmacokinetics 6. When given concomitantly, the anti-Xa activity is additive (42% higher peak when given together, 15% higher when separated by 6 hours). This means:
- Separating doses by 12 hours (i.e., waiting for the next scheduled apixaban dose) minimizes any transient pharmacodynamic overlap
- No washout period is required beyond the normal dosing interval
- The transition is safe with appropriate timing
Dosing Enoxaparin After the Switch
Your enoxaparin dose depends on the indication:
For VTE Treatment:
- 1 mg/kg subcutaneously every 12 hours (standard)
- 1.5 mg/kg once daily (alternative, though twice-daily dosing preferred for acute VTE)
- In cancer patients: Consider 1 mg/kg twice daily initially 7
- Obesity (BMI ≥40): May need dose adjustment or anti-Xa monitoring 8
For VTE Prophylaxis:
- 40 mg subcutaneously once daily (standard prophylactic dose)
- 30 mg every 12 hours (alternative regimen, particularly post-orthopedic surgery)
Renal Dosing:
- CrCl 15-30 mL/min: Reduce to 1 mg/kg once daily (for treatment doses)
- CrCl <15 mL/min: Consider UFH instead, as enoxaparin clearance is significantly impaired
The Reverse Switch (Enoxaparin to Apixaban)
If you need to transition back to apixaban later:
- Discontinue enoxaparin
- Start apixaban at the time of the next scheduled enoxaparin dose 1
- No overlap needed
Common Pitfalls to Avoid
- Don't bridge with both agents: Unlike warfarin transitions, DOACs like apixaban don't require overlap with parenteral anticoagulation
- Don't forget renal function: Both drugs require dose adjustment in renal impairment, but the thresholds differ
- Don't assume equivalence: While both are effective anticoagulants, they have different pharmacologic profiles—enoxaparin requires subcutaneous injection and may need monitoring in certain populations (obesity, renal dysfunction, pregnancy)
- Document the reason: Switching anticoagulants should have a clear clinical rationale to avoid confusion and ensure continuity when the patient transitions back to oral therapy
Special Populations
Cancer patients: Both apixaban and enoxaparin are guideline-recommended for cancer-associated VTE 3, 9, 2. Apixaban is now preferred (strong recommendation) except in patients with luminal GI malignancies where bleeding risk may favor LMWH 2.
Perioperative setting: The 2022 CHEST guidelines address DOAC interruption but don't specifically mandate switching to enoxaparin—bridging is generally not required for most patients 10. However, if parenteral anticoagulation is clinically indicated, the switch is straightforward as outlined above.